Swallowable capsule and method for stimulating incretin production within the intestinal tract
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61N-001/05
A61N-001/06
A61K-038/26
A61N-001/36
출원번호
US-0273917
(2014-05-09)
등록번호
US-8958879
(2015-02-17)
발명자
/ 주소
Imran, Mir A.
Hashim, Mir
Arnsdorf, Emily
출원인 / 주소
Incube Labs, LLC
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
13인용 특허 :
36
초록▼
Embodiments of the invention provide apparatus and methods for stimulating L cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating L-
Embodiments of the invention provide apparatus and methods for stimulating L cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating L-cells to secrete incretins to stimulate or otherwise modulate the production of insulin. Particular embodiments provide a swallowable capsule for stimulating L-cells in the intestinal tract as the capsule moves through the tract. The capsule can include two or more electrodes for providing electrical stimulation to L-cells, a power source for powering one or more components of the capsule, a sensor for sensing the location of the capsule in the intestinal tract; a controller and a waveform generator for generating the electrical signals emitted by the electrodes to stimulate the L-cells to secrete incretins such as GLP-1 to stimulate insulin production for glucose regulation of diabetic conditions.
대표청구항▼
1. A method for stimulating incretin-producing cells (IP-cells) in the intestinal tract of a patient to secrete an incretin, the method comprising: ingesting a swallowable device configured to travel through the intestinal tract and electrically stimulate the IP-cells at any location in the intestin
1. A method for stimulating incretin-producing cells (IP-cells) in the intestinal tract of a patient to secrete an incretin, the method comprising: ingesting a swallowable device configured to travel through the intestinal tract and electrically stimulate the IP-cells at any location in the intestinal tract;delivering an electrical signal from the device to an intestinal wall proximate the device, wherein the signal includes a waveform configured to electrically stimulate the IP-cells in the intestinal tract to secrete the incretin without causing a peristaltic contraction. 2. The method of claim 1, wherein the intestinal wall is a wall of the small intestine. 3. The method of claim 1, wherein the IP-cells comprise K-cells. 4. The method of claim 1, wherein the secreted incretin comprises GLP-1. 5. The method of claim 1, further comprising: modulating a release of insulin in the patient responsive to the secreted incretin. 6. The method of claim 5, wherein the insulin release is modulated by the electrical stimulation of the IP-cells to produce an increase in plasma insulin within 30 minutes of stimulation. 7. The method of claim 1, further comprising: controlling a blood glucose level of the patient responsive to the secreted incretin. 8. The method of claim 1, further comprising: suppressing an appetite level of the patient responsive to the secreted incretin. 9. The method of claim 1, wherein the waveform has a square wave shape. 10. The method of claim 1, wherein the waveform includes a first wave form and a second waveform, the first wave form configured to stimulate the IP-cells without causing a peristaltic contraction. 11. The method of claim 10, wherein the second waveform is configured to generate a peristaltic contraction of intestinal tissue proximate the device, the method further comprising: advancing the device within the intestinal tract using the generated peristaltic contraction. 12. The method of claim 11, wherein the second waveform occurs substantially non-concurrently with the first waveform. 13. The method of claim 11, wherein the second waveform is generated responsive to a velocity of the device moving through the intestinal tract. 14. The method of claim 13, wherein the velocity is measured using an accelerometer disposed on or within the device. 15. The method of claim 1, further comprising: determining a location of the device in a GI tract, wherein the signal is delivered responsive to the location of the device in the intestinal tract. 16. The method of claim 15, wherein the location is a small intestine. 17. The method of claim 15, wherein the location is determined using a sensor. 18. The method of claim 17, wherein the location is determined based on at least one of a sensed pH or sensed pressure applied to the device surface by intestinal wall tissue. 19. The method of claim 1, wherein the ingestion of the device is coordinated with a ingestion of food. 20. The method of claim 19, wherein the device is ingested during a selected time period before, during or after the ingestion of food. 21. The method of claim 20, wherein a time period is selected to coordinate the stimulation of the IP-cells with the absorption of nutrients from the food into a blood stream. 22. The method of claim 1, wherein the device comprises a swallowable capsule. 23. The method of claim 1, wherein the device comprises a controller, at least one electrode and a waveform generator. 24. A method for stimulating incretin-producing cells (IP-cells) in the intestinal tract of a patient to secrete an incretin which modulates a release of insulin, the method comprising: ingesting a swallowable device configured to travel through the intestinal tract and electrically stimulate the IP-cells at any location in the intestinal tract;delivering an electrical signal from the device to a intestinal wall proximate the device, wherein the signal includes a waveform configured to electrically stimulate the IP-cells in the intestinal tract to secrete the incretin without causing a peristaltic contraction of a small intestine; andmodulating the release of insulin in the patient responsive to the secreted incretin. 25. The method of claim 24, wherein the insulin release is modulated by the electrical stimulation of the IP-cells to produce an increase in plasma insulin within 30 minutes of stimulation. 26. The method of claim 24, wherein the incretin comprises GLP-1. 27. The method of claim 24, further comprising: increasing the insulin sensitivity of the patient's body tissue responsive to the secreted incretin. 28. The method of claim 24, further comprising: controlling a blood glucose level of the patient responsive to the secreted incretin. 29. The method of claim 24, wherein the IP-cells comprise K-cells. 30. A method for stimulating incretin-producing cells (IP-cells) in a intestinal tract of a patient to secrete an incretin which suppresses an appetite level of the patient, the method comprising: ingesting a swallowable device configured to travel through the intestinal tract and electrically stimulate the IP-cells at any location in the intestinal tract;delivering an electrical signal from the device to the intestinal wall proximate the device, wherein the signal includes a waveform configured to electrically stimulate the IP-cells in the intestinal tract to secrete the incretin without causing a peristaltic contraction of the small intestine; andsuppressing the appetite level of the patient in response to the secreted incretin.
Wright Jeremy C. (Los Altos CA) Eckenhoff James B. (Los Altos CA) Maruyama Frederick H. (San Jose CA) Peery John R. (Stanford CA), Delivery system comprising means for controlling internal pressure.
Lewkowicz,Shlomo; Gat,Daniel; Kraizer,Yehudit; Gilad,Zvika; Leuw,David; Meron,Gavriel; Glukhovsky,Arkady, Device and method for examining a body lumen.
Hugemann Berhhard (Frankfurt am Main DEX) Schuster Otto (Bad Soden DEX), Device for the release of substances at defined locations in the alimentary tract.
Pasricha Pankaj J. (Columbia MD) Kalloo Anthony N. (Glenndale MD), Device for treating gastrointestinal muscle disorders and other smooth muscle dysfunction.
Imran, Mir; Herrmann, Peter; Syed, Baber; Williams, Timothy H.; Ong, Chang Jin; Method, Greg, Device, system and methods for the oral delivery of therapeutic compounds.
Prausnitz, Mark R.; Allen, Mark G.; Henry, Sebastien; McAllister, Devin V.; Ackley, Donald E.; Jackson, Thomas, Devices and methods for enhanced microneedle penetration of biological barriers.
Yokoi,Takeshi; Takizawa,Hironobu; Segawa,Hidetake; Adachi,Hideyuki, Encapsulated medical device and method of examining, curing, and treating internal region of body cavity using encapsulated medical device.
Lehmann Grard (Neuville de Poitou FRX) Metais Jol (Monts Sur Guesnes FRX) Meunier Jean-Francois (Noisy le Grand FRX) Gautier Jean-Philippe (Ozoir la Ferriere FRX), Implantable drug-dispensing capsule and system facilitating its use.
Truex Buehl E. (Glendora CA) Gibson Scott R. (Granada Hills CA) Weinberg Alvin H. (Moorpark CA), Implantable medical device having shielded and filtered feedthrough assembly and methods for making such assembly.
Brister, Mark C.; Quintana, Nelson; Patel, Kaushik A.; Drake, Neil R.; Llevares, Antonio C.; Markovic, Dubravka; Rasdal, Andrew P.; VandenBerg, Amy D. L., Intragastric device.
Saffran Murray (Toledo OH) Neckers Douglas C. (Perrysburg OH), Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointest.
Nicolaides Ernest D. (Ann Arbor MI) Tinney Francis J. (Ann Arbor MI) Kaltenbronn James S. (Ann Arbor MI) DeJohn Dana E. (Ann Arbor MI) Lunney Elizabeth A. (Ann Arbor MI) Roark W. Howard (Ann Arbor MI, Modified tripeptides.
Eckenhoff ; deceased James B. ; Holladay Leslie A. ; Leonard ; Jr. John Joseph ; Leung Iris K. M. ; Tao Sally A. ; Magruder Judy A. ; Carr John P. ; Wright Jeremy, Peptide/protein suspending formulations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.